好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Video Game Based Upper Extremity Assessment Tool for Individuals with Neuromuscular Disease
Muscle Disease/Neuromuscular Junction
P07 - (-)
039
BACKGROUND: New treatments are emerging for neuromuscular diseases such as gene therapy, small molecules and drugs. Clinical trials are being conducted using timed walking as a primary outcome measure due to the ease of administration, ability to quantify distance, and established validity. Unfortunately, participation in clinical trials is not equally accessible to all individuals due to the lack of a of reliable, valid and sensitive upper extremity measure for the non-ambulatory population. It is essential that this gap in knowledge be filled, as upper body movement is required for many activities of daily living impacting quality of life across the lifespan and abilities in individuals with neuromuscular disease. The Microsoft Kinect Windows 7 used for this project is a controller-free gaming device that projects an infrared reference matrix that is reflected off of the person and generates a high-resolution depth map of each pixel allowing for tracking of movement. Software was designed to capture positional data while the subject plays a custom designed video game.
DESIGN/METHODS: Test retest reliability of subjects with upper extremity impairment due to a neuromuscular disease and controls was evaluated during repeated trials of the game in the same day. Performance was compared to marker based motion capture and traditional upper extremity assessments.
RESULTS: Pilot data were able to differentiate individuals based on Brooke's upper extremity level. Comparison to marker- based motion analysis showed a consistent over estimation of average velocity by 20%.
CONCLUSIONS: Initial data suggest that this assessment if a reliable and valid tool for measuring upper extremity function in subjects with neuromuscular disease.
Authors/Disclosures
Linda P. Lowes, PT PhD
PRESENTER 		The institution of Ms. Lowes has received research support from Sarepta Therapeutics.
Lindsay N. Alfano, PT (Nationwide Children'S Hospital) Ms. Alfano has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for ATOM International, Ltd (Amicus Therapeutics, Catabasis, Genethon, Italfarmaco, NS Pharma, Pfizer, PTC Therapeutics). Ms. Alfano has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sarepta Therapeutics. The institution of Ms. Alfano has received research support from Novartis Gene Therapies. The institution of Ms. Alfano has received research support from Sarepta Therapeutics. The institution of Ms. Alfano has received research support from Audentes Therapeutics/Astellas Gene Therapies. Ms. Alfano has received intellectual property interests from a discovery or technology relating to health care.
No disclosure on file
No disclosure on file
No disclosure on file
Kevin M. Flanigan, MD, FAAN (Nationwide CHildrens Hospital) Dr. Flanigan has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Solid. Dr. Flanigan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Armatus. Dr. Flanigan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Avidity. Dr. Flanigan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Dyne. The institution of Dr. Flanigan has received research support from Ultragenyx . The institution of Dr. Flanigan has received research support from Solid Biosciences. The institution of Dr. Flanigan has received research support from Dyne Therapeutics. The institution of Dr. Flanigan has received research support from Avidity.
Jerry R. Mendell, MD, FAAN (The Research Institute at Nationwide Children's Hospital) Dr. Mendell has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Vertex. Dr. Mendell has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novartis. Dr. Mendell has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Sarepta Therapeutics . The institution of Dr. Mendell has received research support from Sarepta.
Klaus Seppi, MD Dr. Seppi has received personal compensation in the range of $500-$4,999 for serving as a Consultant for ONO . Dr. Seppi has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lundbeck. Dr. Seppi has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for BIAL. Dr. Seppi has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AbbVie. Dr. Seppi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. Dr. Seppi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche. Dr. Seppi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Bial. Dr. Seppi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Teva. The institution of Dr. Seppi has received research support from MJFF. The institution of Dr. Seppi has received research support from EU. The institution of Dr. Seppi has received research support from FWF Austrian Science Fund,.